489 related articles for article (PubMed ID: 27885553)
1. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence.
Jacobs I; Petersel D; Isakov L; Lula S; Lea Sewell K
BioDrugs; 2016 Dec; 30(6):525-570. PubMed ID: 27885553
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal Antibody and Fusion Protein Biosimilars Across Therapeutic Areas: A Systematic Review of Published Evidence.
Jacobs I; Petersel D; Shane LG; Ng CK; Kirchhoff C; Finch G; Lula S
BioDrugs; 2016 Dec; 30(6):489-523. PubMed ID: 27807766
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
[TBL] [Abstract][Full Text] [Related]
4. Biosimilars for the Treatment of Cancer: A Systematic Review of Published Evidence.
Jacobs I; Ewesuedo R; Lula S; Zacharchuk C
BioDrugs; 2017 Feb; 31(1):1-36. PubMed ID: 28078656
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars for the treatment of psoriatic arthritis.
Cantini F; Benucci M; Li Gobbi F; Franchi G; Niccoli L
Expert Rev Clin Immunol; 2019 Nov; 15(11):1195-1203. PubMed ID: 31625769
[No Abstract] [Full Text] [Related]
7. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
8. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
Papamichael K; Van Stappen T; Jairath V; Gecse K; Khanna R; D'Haens G; Vermeire S; Gils A; Feagan BG; Levesque BG; Vande Casteele N
Aliment Pharmacol Ther; 2015 Nov; 42(10):1158-69. PubMed ID: 26365281
[TBL] [Abstract][Full Text] [Related]
9. Biosimilars: a systematic review of published and ongoing clinical trials of antipsoriatics in chronic inflammatory diseases.
Nast A; Rosumeck S; Seidenschnur K
J Dtsch Dermatol Ges; 2015 Apr; 13(4):294-300. PubMed ID: 25819235
[TBL] [Abstract][Full Text] [Related]
10. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
11. Review of Biosimilars of Adalimumab.
Kaushik VV
J Assoc Physicians India; 2017 May; 65(5 Suppl):15-21. PubMed ID: 28836746
[TBL] [Abstract][Full Text] [Related]
12. Can We Extrapolate Data from One Immune-Mediated Inflammatory Disease to Another One?
Magro F; Coelho R; Peixoto A
Curr Med Chem; 2019; 26(2):248-258. PubMed ID: 30381062
[TBL] [Abstract][Full Text] [Related]
13. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
14. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars in rheumatology.
Araújo FC; Gonçalves J; Fonseca JE
Pharmacol Res; 2019 Nov; 149():104467. PubMed ID: 31568820
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab Biosimilars in Europe: An Overview of the Clinical Evidence.
Bellinvia S; Cummings JRF; Ardern-Jones MR; Edwards CJ
BioDrugs; 2019 Jun; 33(3):241-253. PubMed ID: 31111422
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars for the Treatment of Psoriasis: A Systematic Review of Clinical Trials and Observational Studies.
Phan DB; Elyoussfi S; Stevenson M; Lunt M; Warren RB; Yiu ZZN
JAMA Dermatol; 2023 Jul; 159(7):763-771. PubMed ID: 37256582
[TBL] [Abstract][Full Text] [Related]
18. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
Avila-Ribeiro P; Fiorino G; Danese S
Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
[TBL] [Abstract][Full Text] [Related]
19. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
